葵花药业：关于全资孙公司广东葵花医药有限公司减资进展公告

Core Viewpoint - The company announced a reduction in the registered capital of its wholly-owned subsidiary, Guangdong Kewang Pharmaceutical Co., Ltd., from RMB 43 million to RMB 38 million, which has been completed and documented with the local market supervision authority [1]. Group 1 - The fifth meeting of the company's fifth board of directors is scheduled for April 24, 2025, to review the proposal regarding the capital reduction [1]. - The capital reduction process for Guangdong Kewang has been completed recently, and a new business license has been issued by the Baiyun District Market Supervision Administration of Guangzhou [1].